Evidence map›Paper›PMID 23161124›Full record

Trial reportInternational journal of clinical pharmacy2013

Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial.

Aline Oliveira Magalhães Mourão, Wandiclécia Rodrigues Ferreira, Maria Auxiliadora Parreiras Martins, Adriano Max Moreira Reis, Maria Ruth Gaede Carrillo, Andrea Grabe Guimarães, Lisiane Silveira Ev

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 11 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 11 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Impact of integrating pharmacists into primary care teams on health systems indicators: a systematic review.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aline Oliveira Magalhães MourãoPost-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil.
Wandiclécia Rodrigues Ferreira
Maria Auxiliadora Parreiras Martins
Adriano Max Moreira Reis
Maria Ruth Gaede Carrillo
Andrea Grabe Guimarães
Lisiane Silveira Ev
Universidade Federal de Ouro Preto · BRUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients.

objectiveTo evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes.

settingSix primary care units of the Brazilian public health system, Ouro Preto, Brazil.

methodAn open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C.

resultsA total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors.

conclusionsThis study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.

Indexed as

Pharmaceutical ServicesAgedBrazilDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansMaleMiddle AgedGlycated Hemoglobinhemoglobin A1c protein, human

Identifiers

PMID23161124
OpenAlexW2024770222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.